CytomX Therapeutics (CTMX) 8 May 242024 Q1 Earnings call transcript

Good day, and thank you for standing by. Welcome to the CytomX Therapeutics First Quarter 2024 Financial Results Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Chris Ogden, CytomX' Senior Vice President, Finance and Accounting. Please go ahead.

you. Thank thank us. and for you afternoon, joining Good

undertake they Before that the our our of Important be during I to that first no set would are the that recent making recent and are our predict risks or quarter inherent of remind We at which filings we at everyone in release whether new like to are result a a future, afternoon, to and this issued relate many statements. difficult highlight developments obligation forward-looking uncertainties progress we CytomX. with subject any a risks, SEC control. XXXX statements, Because to uncertainties most future forward-looking begin, otherwise. Earlier financial update forward-looking statements this are summary and and call, includes of to we forth press sec.gov. will public as of outside information, results

Phase release focus We escalation of also primary associated SEC. read press encourage monotherapy a today's the been data today's issued positive call. We today have and with everyone filed Ia which be materials, the releases for the to dose CX-XXX, will press initial which announcing

Chu, CX-XXX dose open call releases and SEC under Chief study outline masked engagers. give of Executive press closing of Q&A. the T-cell Dr. and up Sean provides on an Chief then CytomX' McCarthy, will on and are update be for CytomX' we Sean Phase and strategy our Medical for and the the escalation News Officer. Officer CytomX' recording Wayne broader and overall I an the Sean the the me our also Additionally, provide before comments call website. With on will filings pipeline this update Investors and Wayne Dr. found can section call Chairman, today

With that, over turn the to now I'll call Sean.

our in CX-XXX. CytomX masking our pleasure QX, It's is therapeutic highly therapeutic Probody Phase focused good activation. our initial strategy, and Chris, needs a through everyone. window progress from during antibody today findings improve for T-cell afternoon, modalities on of platform, major targeted engager our including to our the EGFR share designed oncology here using considerable to Probody a unmet I multiple be study antibody Thanks, to tumor-localized addressing proprietary

We to new are therapeutic leveraging therapies Probody ADCs masked T-cell and cytokines. on platform develop engagers, our masked cancer discover and based masked

Our than XX and active including encompasses broad rates. significant and commercial pipeline more stage clinical X retained programs, deep molecules

Moderna corporate we're Astellas, Strategic to partnering Amgen, is our our Probody Bristol-Myers therapeutic programs. be Squibb, of Regeneron components on and proud strategy, and closely multiple with long-standing working

be to end with We our runway strong is our of with capabilities, position collaborations continue in any investment of milestone technology or in XXXX, which organizationally integrated cash QX, experienced continued not transforming the cash partnership and very safer, any a strong our with core the end $XXX of new including effective funding. CytomX therapies. dedicated provides a financial vision more lives to payments under of deeply potential million existing R&D at team to

tumor platform EpCAM cell-mediated activity T cancer. CX-XXX therapeutic case seeks need The of in X. EpCAM in the design target interferon experience the effector impact cell is brings more itself. unmet tumors EGFR strategy meaningful product high make potent of together expressing potential of not target via we types, that Slide of integrates conventional killing potentially including in strategy as EGFR conditionally-activated Probody have informed antibodies T of cell is those oncology. CX-XXX activity. CX-XXXX leverages masking a colorectal areas Topo-X our for target with a ideally mechanism this the goal the to the alpha, suited, inhibitor high key is payload, with with CDX cytokine believe, engagement the potency cancer function positive a and effective of decade masked our to selection, Moving and CytomX balance by using than to the which of ADC to shown like which

masked neck microenvironment carcinoma to cell potential locally for cancer interferon was melanoma, responses and across including renal multiple is cell the activate with head types, extremely quarter squamous drive Our intratumoral designed immune an productive to and carcinoma. QX CytomX.

is our topic we're escalation T-cell to Today, our executing data initial are our update of EGFR-CDX We monotherapy and here full making announcing plans, Ia our engager the solid progress across tumors, of for dose positive we're CX-XXX, pipeline. the and this main today. breadth in Phase

our I XXXX. EpCAM, XXXX, with Phase QX, of in alpha, I during CX-XXX, XXX study Phase activities supply the is the and in continued first we ADC the with cohort in focused interferon also to initiation in half progress an colorectal Merck of CX-XXX for Initial addition exciting data is we and XXXX. In program cancer, targeting CX-XXX, this study our cleared execution the study the of anticipate clinical Also agreement data last agreement QX, during first largely KEYTRUDA from night. anticipated that dose combination and including masked to for announced initial with

across Zhen alliance. Dr. continue under engaging with Board during Astellas collaboration cell $XX preclinical to collaborations, We first on bispecific the was to progress that progress earning programs in Su We're T excellent our including our welcome our make to also X for the QX. milestones million delighted of

clinical for we months XX XXXX all productive and ahead of is CytomX very pipeline XX fronts momentum, a to have our current to So gaining us. start a really exciting really and on

hematologic clinical bispecific T-cell to engaging for benefit and our enormous antibodies, have malignancies. now cell potential Moving the of demonstrated cancer T course, treatment of in strategy. engager first meaningful

tumor solid potency tissues this however, challenges in the can are significant for tumor really potency to Looking solid normal antigen tumors, there to T-cell also And overcome. Notably, and high bring for toxicities some modality progress. be time engagers interest clinical break lead this at see taken meaningful where through it's in to of very T-cell engagers, to the present. landscape may

cells solid in tumor tissues neurotoxicity of cytokine antigen-binding CDX index. in program broad-based the T-cell masking tumors a thereby is in CDX binding in also release T-cell and syndrome, on also systemic engagers form we from therapeutic the for have normal ICANS. At engagers binding improving limitation decrease decreased key on to periphery, resulting Another T and focused CytomX, to

effector systemic in long-standing which into to of was walking antibody CX-XXX BMS masked set the reason EGFR the and internal to had of that first this reduction publication focused through We require EGFR this programs, potent addition a a of the more interest version. CX-XXX encompassed realization to molecule. We've with our of in like Amgen, T-cell potential engager. a target to lead leading seminal program rash and a as the strategy skin EGFR I'd the masking history the so at Probody our this and is area, realized minutes unmasked CX-XXX. the much showed space. for has CytomX, the and would we're for EGFR-CDX successful we cetuximab structure monospecific ever bispecific exciting our of antibody the the for concept marked the us stage evolution potential compared working more on the to a antibody binding in mechanism, EGFR engager Regeneron findings partners, These In few Astellas, our be masked in spend now T-cell

slide our concept to fine-tuning preclinical is Fc refined for the program somewhat expected overall depth domain, be from like early platform binding molecular optimization Amgen's region, so CX-XXX cleanable our has has lead cell EGFR small next different of generally. are each our for CDX we partner, proof window. CX-XXX half-life. of recap publish binding unique using reflecting on are with shown XXX. in molecule our to of of slide the domain a research domain. to did protease also it Shown peptides. binding actually the structure domains Amgen. The shows that similar therapeutic strategy tarlatamab CX-XXX antibody Furthermore, this for and an and cancer. substrates structure is in lung have This the X architecture platform the results collaboration and an right cancer in impressive would and therapeutic of subsequently has with this preclinical demonstrate of We in Both and X masked concept, the an

The concept or window. localization leads of are creation improvement the proteases. normal This tumor drug is tissue, in activated that mask to by therapeutic masking binding to the in tumor tumor reduces a tissues whereas target removed

the EGFR-CDX it's shown is the pair, antigen models. been that bispecific highly unmasked toxic previously For in preclinical

creating So we for believe, our a essential window. therapeutic masking strategy is,

terms In and EGFR rash we're looking toxicities, to side gastrointestinal antibodies mitigate, of to known the are cause effects. well

toxicities, is, of And specifically our our above. course, looking so ICANS. it really to Grade strategy and CRS for EGFR particularly designed serious and X With to to CDX, strategy we've limit masking been regard live masking out

for and our to let me Before the Wayne, to CX-XXX. I study over achievements I of date Phase high-level hand goals review

the been you see made and the engagers the high the and EGFR, of safety potency #X we've XXX, has will Wayne's expression Given T-cell evaluate for as progress, study goal of really widespread presentation. of to from excellent

We've mentioned our and EGFR believe manageable no consistent dosing. remarkably, rather also explored the level seen CRS see believe have seen some CDX in Again, work dosing, or our CRS pleased and of step were at We prior all. to earlier. we and EGFR step-dosing any very limited of because cohorts, very marketing that achieving doses. non-step EGFR And with of have therapeutically evidence success We've active strategy shows these dose schedule. Furthermore, have we've I masking. limited toxicities, we we been at published not in non-step successful no of seen is while success this us with this ICANs masking

signs Phase course, our of initial of look of for has, study #X been I antitumor activity. Goal to

in early or emphasize tumor cancer, EGFR. All evidence said, this confirmed announce study we've for immunotherapy. would date, including is first-in-man range As XXX, inhibition to activity for of of anticancer a signs the encouraging. responsive matter, unselected any or EGFR enrolled, tumor heavily tumor and and population to patient be delighted types in very tumor very to very difficult RECIST months, this to want stabilization type treat typically of I that we've I said Phase that to to is responses encouraging is that a shrinkage recent in pancreatic today not in and that for pretreated is we're study

Moreover, we're at are the read-through, platform the of providing we supportive action believe, with programs proof mechanism concept to our as T-cell initial engager, CytomX. assessments of crucial other of of pharmacodynamics on working many CX-XXX a masked of

work We're and we're initial Ib engager CytomX enroll goal sharing study Phase and that field. this see of next a data expansions. for dose promising very to determine I recommended tumor is We Phase escalate II the and development T-cell ongoing. positions define at Phase today the in is the CX-XXX, of as Importantly, forefront the step multiple our to continuing types. this And plans to dose

me hand review let to to over Now detail. Wayne some in data the

translational and were dose clinical thanks, everyone, dose key in with known and slide observations opportunity to with Sean, share early eligibility summarizes Thanks, objectives. the Patients enrolled. escalation This study expression and EGFR the study. the for scheme, ongoing our tumors escalation criteria

expression. were not patients selected based on EGFR However,

Dose tested. every initiated using CX-XXX from non-step schedule escalation X milligrams X was X micrograms were in once dosing through starting weeks, doses dosed a was which

presented represents escalation discuss slides, target with as total target XX-milligram will safety step-dosing current escalation dose. in continued schedules with of a And dose Various the testing an dose dose the milligrams. from cohorts using of every we which subsequent the initial administered X and As were the efficacy schedule data weeks. The continues a step-dosing escalation Sean XX-milligram target dose today mentioned, enrollment dose was XX the of X CX-XXX target dose. data after through tested,

on Selected baseline has or non-step term which unresponsive were been immune to characteristics dosing I are patients such immune patients as be will escalation to CRC majority with demonstrated in in of colorectal those enrolled out, this cohorts stable The checkpoint MSS shown inhibitors. here cancer, microsatellite slide. therapies which from enrolled for

evidence cohorts, escalation as other focus known on activity types tumor early with with step-dosing patients have tumors EGFR we expression. well With as to clinical with begun of

observed are increases total received had essentially right were prior As CX-XXX dosing profile to days. This or cycle the of consistent increasing CX-XXX circulation exposure dose of striking. that was Probody. from The the toxicities apparent in of and observed. a PD-X therapy. Early X Similarly, Musculoskeletal shown the therapy many received show the CX-XXX was Through were other X mitigate refractory ability curves Grade proportion Notably, and CX-XXX systemic shows of and masked exists left The CRS dose here any X was EGFR by and experienced X musculoskeletal and events dosing, association X non-step dose-dependent with except CRS, graph. dose-dependent with engager tenosynovitis on and observed to arthralgia virtual T-cell between X associated and study, level. safety circulating events are concentrations X-milligram levels typical appear of X for summarizes late-line ICANs with the only drug in were medication With of of adverse dose data as level X.X intact The no or or as It and the and X direct the the shows ICANS. cancer with masking therefore, grade advanced target-mediated the in masked considerable linearly disposition. patients prior dosing the X-milligram increase a schedule CDX, superimposable, the CX-XXX at overall median X the X-milligram the to such change grade first-in-human observed. Low-grade for at absence where data I CX-XXX directed CRS as X-milligram IL-X of PD-LX dose-limiting tenosynovitis the only clearance adverse last X much a reflects for indicating disease, the or Grade graph level. Probody CRS that X observed their with evident. rash quite curves level, design. graph rash, other fever evidence Grade dose This EGFR and is Grade Phase such a where Grade in prior CRS tolerability without observed. signs circulating escalation addition dose, corticosteroids of ICANS at ICANs and a Even X.X analyte and/or was pharmacokinetic no form. therapies, patients or on patients of clinical be non-step ICANS. CRS that, patients X-milligram Grade with CX-XXX predominantly in dose CRS enrolled intact is characterized PK any during less contrast shown indicating non-step the X had the intact The dose that prophylactic with to events schedule. rash in slide associated the any level, important IL-X treatment-related was at the mention or no administered circulating estimates half-life is no the with arthritis symptoms toxicity to Preliminary in escalation, total in transient

clear a measures step-dosing therapeutic efficacious an tocilizumab protocol, events, per doses. These to required this of to CX-XXX levels allow and safety and target change maintain severity related outpatient more profile to ratios any practice. favorable and specifically adverse convincingly eliminating and increase and ICANS masking not CX-XXX the musculoskeletal with Moreover, profile. observations continuation an dose constitute grade potentially to and tolerability resulted which incidence observed. doses in here effectively CX-XXX a treatment on demonstrated monitoring to management were no enable higher prophylaxis emerging has not administration continues X events mitigated which schedule, of Impressively, and treatment-related for CRS did CX-XXX dose-limiting engagers. and the Overall, were no adverse regard, acceptable to mitigate schedule was Grade to in of events target demonstrate escalation events setting. CX-XXX and is that quite CX-XXX, adverse adverse effectively the many substantially of of ICANs hospitalization toxicities data T-cell profile of ICANS, this maintain the necessitated be on presented discontinuation. Overall, observed broad CRS In of the non-step the escalation importantly, with enabled safety benefit used masking continuing safety higher on CRS reported, doses, the are target no Based no escalation the date dosing while musculoskeletal and by higher and mandatory during and at dose or index,

in with extremely observed patients patients of encouraging, profile, to of are in In observed cancer observed that by CX-XXX CX-XXX activity highly pancreatic with date therapies. outcomes activity, poor pancreatic current recurrent safety with compelling favorable given remain the context adenocarcinoma. metastatic a The we advanced available highlighted signs with responses anti-tumor

treatment, of a is treated a milligrams measurable on reduction here target across tumor doses plot in the Confirmed X schedule dose and control. X X now efficacy-evaluable remain burden an of partial schedule was study the were and on with in note, and responses X non-step step-dosing patients, patients. had Shown observed X patients target had range on Of both schedules. detail. patient will with the RECIST X.X patients X milligrams in per treated had X One on XX% of greater discuss these the a treated step-dosing tumor in criteria waterfall all dosing a non-step reduction patients burden. Furthermore, and disease was of XX% X a of we second and

and X administered X X syndrome first thereafter. schedule X The adenocarcinoma. pancreatic ICANS. The surgery, The of Prior X describes experience milligrams experienced target partial or XX-year-old day therapy thereafter not and confirmed with CX-XXX X.X prior later patient milligrams or step-dosing administration then related a X chemotherapy. cycle a a a received patient metastatic after on arthralgia, delay The weeks -- lines the case patient cytokine therapies in resolved week in on administered Grade this X of but radiation X every dose did and Grade weeks response included patient X of release corticosteroids. with

date. to with scan. scan deeper months achieved the patient response this confirmatory mentioned, having I received treatment tumor observed images, As CT And of reduction burden over remains as a CX-XXX patient the on in shown CT treatment partial the X in as

received X a metastatic no treatment papulopustular lines day on ICANS musculoskeletal illustrates X, X.X with X with adenocarcinoma with milligrams or and milligrams systemic next pancreatic events X case of thereafter. patient X schedule patient which every CX-XXX day had weeks day on CRS, The on and who tolerated on treatment. received a X, administered CX-XXX prior rash, with milligrams durable chemotherapy. with step-dosing XX The topical Grade This CX-XXX stable in XX-year-old XX well patient only and resolved disease

The figure months translational to reduction CAXX and of CX-XXX a measurable mechanism of of the than baseline. date. Preliminary and of of within And on as activity. with overall obtained improvement maintain serum cell This continued the patient growth antitumor and with patient benefit X.X additional T engager clinical deep cells in image and partial of evidence to activity achieved a supporting microenvironment, stable dark can indicates red, from the in blue prior able left see, markers showed light is biopsy from in cells pancreatic level greater the remains pancreatic levels positive XX% disease in over a information action included who blue. T-cell consistent magenta tumor to received you no that status The performance pharmacodynamic T biopsy treatment with treatment is adenocarcinoma. an treatment colors cancer on in immunofluorescence a patient indicate having CX-XXX cell to contribution their The was data indicating CDX T tumor CX-XXX a cancer high response. pretreatment

engagers. Taking reduction it the evaluable the to of CDX-positive following on T X.XX cells of doses compelling CX-XXX with milligrams. treatment mechanism response. trafficking where The is of CX-XXX patients consistent the action of to target shown sites with the pancreatic with RECIST activity peripheral equal early relates with or a greater here CDX-positive CX-XXX T patients as step right response X.X plot from confirmed T tumor pancreatic had the treated periphery efficacy among cells partial than waterfall back T-cell from greatest adenocarcinoma cells shows the Both a of figure patients but to reduction of as the peripheral

doses in observed reductions were measurable and CX-XXX responses with of objective with early lung cancer. cell currently pancreatic in no cancer signals X total in patients in other observed types, X were target esophageal in with that patients the also are patients CRC, measurable compelling We disease disease tested of including in partial While the tumor efficacious. that pancreatic non-small observed are were believe activity responses. Reductions carcinoma cancer burden patients, and burden the

the study EGFR result, enrollment tumor will to with continuing in types other a and upper focus forward As patients derive addition slide cancers. This neck with summarizes time and treatment. moving benefit to positive GI for continue pancreatic on again, patients cancers head with pancreatic to with cancer, adenocarcinoma patients patients cancer ongoing study treatment the on including that CX-XXX, clinical enroll lung CX-XXX highlighting with treated

has biopsies on with had with of taken in as minimal to retains baseline from immunofluorescent CX-XXX MSS activity CX-XXX which illustrated CX-XXX this patient CRC, Importantly, pharmacodynamic in are a date its slide, while images treatment. activity while clinical CRC at and patients

meaningful data masking strategies dose tumor. contrast, ability clearly potential can we a of the action early the a treatment is in are T for and of is CX-XXX in in which a I the the see indicative broad In the CRC. In absence you for a index. maintain safety encouraged substantial biopsy on-treatment at tumor EGFR has notable cancers This cells increase is clinical therapeutic to the within CDX-positive this by of ongoing of demonstrates within of As complete Phase showed baseline, number of observation expression tissues combinations the addition profile, summary, in the normal the of escalation. mechanism to CX-XXX the CDX-positive almost cells given T tumor. of CX-XXX of the demonstration favorable clear very

with CX-XXX dose. II observations including clinical adenocarcinoma pancreatic cancer. but determine and The only promising demonstrating of to of CX-XXX activity the clinical early partial valuable been early have Phase confirmed also to patients in translational the the CX-XXX, direction of action, ultimately early extremely in recommended in provide highlighted plans clear efficacy not Second, metastatic and demonstration has responses pharmacodynamic activity and by mechanism colorectal

that, positive future of in tumor of clinical with concluding will which to to pancreatic Sean immune will for I based inform prior enrollment development considerations on data And includes turn in it types other also include enrollment continued remarks. more back are combination that Together, this therapies now cancer CX-XXX, experience. strategies. And responsive and EGFR these

Great. Wayne. Thanks,

beginning we're this potential a drug as such many by is moment, with a with staying activity And data at of novel generate have CX-XXX of So for expression for EGFR do our and to our we're can progress just the redoubling with confirmed date, types. very additional candidate. drug target excited tumor developing a in more learning what clearly types we broadly explore patients. to tumor monotherapy in CX-XXX candidate we're We efforts XXX. high

data potential future also unlocks Our for Wayne strategies mentioned. as combinations,

for This moment Focusing one difficult today, of the is on cancer. areas greatest a it's and pancreatic treat. of unmet needed notoriously oncology to

rates respond single the and Second-line does reiterate not the digits, To in matter to today, our mPFS war new These pursue very of what a data signal CX-XXX exactly the showing people either just in patients. integrated response of this on do, devastating afflicted we Probody designed embodiment anti-EGFR pancreatic overall with survival difficult-to-treat cancer were to is months. aggressively importance shared masked to that immunotherapy form, and be to alone. of Probody in late-stage how this disease, these the for enabled frontier we could tumor can cancer. pharmacology bispecific have cancer that X in is strategies unique the or we by type. plan technology, shown elicit we CX-XXX when into combine T-cell and meaningful was today responses benefit results impact antibodies powerful our What masking of are brings the an engagers together a pancreatic these mechanisms X can

in playing through looking part preclinical see to promising our discovery providing not a developing cell break showing at to additional and CX-XXX we're we are this We in step we exciting development. deal many year. the pipeline anticipate a into starting T-cell and asset also initial we're full through promising the data XXX And engager our XXXX, our programs on CytomX. to with later forward progress overall. highly today and solid out XXX back additional T at this also only CytomX engagers it's portfolio an T-cell and cancers, also great update field, to as zooming of look Now be in here advancing but engagement this

owned remind also progress today's We're course, I of mind. keep and like fronts. already other XXX and Phase multiple are very focus. up, in XXXX, for a CX-XXXX We're wrap in been masked wholly But Of assets. for to second I lot masked CX-XXX our to cohort making programs data update has I'd our before everyone on clinical Phase CX-XXX, with in initiation interferon we And XXXX. our anti-EpCAM is Ia both imminent. anticipate our ADC

living like work to for truly the close an innovative in CytomX everyone sincerely on I thanking for investigators. also vision. families with a I'd delivering team. benefit to commitment a team intensely this such work talented with who to focused people involved it's cancer our to and and privilege our thank want by our their the patients is of join studies, The pipeline their

And for that, open go let's with operator, and ahead up the call questions.

Lawson [Operator Instructions] Your Peter from first of question, it comes line from the Barclays.

can to responses seen tissues so you've And do also as you pancreatic other responses engagers. benefit special can masking deeper something The do in other seen, think do you -- think that you T-cell far about think extend then well? you exciting. the you've cancer? Or Really there's get

great questions. Yes, Peter, Thanks.

programs, obviously very we're that and that, other to be will the case. the the Regarding read-through optimistic extension

and one I You've got engagers. We've partners, start us. strong learned start work it's XXX, for and T-cell a think in in got lot very programs. of internally with somewhere, And to multiple with lot we're a mentioned, a as the both we've doing this our clinic. We've

majority the in fact, partnered engagers. of work In T-cell is our

few make would years. next additional the progress we to expect So here over substantial

as is I'm question. it's about tumor But see thought a lot of we've if not of cold interesting or not might that, great to typically -- It's suggesting is immunology to like. been case. an you an beginning In think thinking this, a done be -- that I the pancreatic, pancreatic terms desert, immunologic of obviously. actually, And evidence

at Roche updated look data, If AACR. you at recently BioNTech most the vaccine

an that suggests to EGFR, It no with directed anti-EGFR cancer each in that been -- But of there. microenvironment. And with interesting. neoantigens course, one looks of there it there's is pancreatic some immunologic has break really also It's are able well, there through therapy. like this combination

EGFR would So something tumor we to very We're that does this not type. CDX XXX. indicate in absolutely about could in particular others this that unique it But early be respond study. very still think and not

mentioned, progress engagers interesting. lot strategies is cold be a would the They're tumor. we patients colorectal combination showing looking As to Wayne That's today. with yet in CRCs, has made data so T-cell another that all of MSS there. Not been we're

far types the it's As are just very, days. other as very tumor concerned, early

patients to where For like just the escalation date. X study in I'd example, dose lung, have we

so already done One just of low probably the only those experiment We've was relevant. not treated -- yet. haven't a dose, very we at

continue going multiple time. in we're define enrolling types over multiple pursue across the activity tumor drug tumor So Ia we types hopefully signal the of and both the pancreatic to as Phase to across keep

And the or it that EGFR of with expression depth Is the correlated microenvironment? then is tumor Great. responses.

the measurable EGFR One the that's tumor a of this X And EGFR clear we it's patient the basis patients in all expression. continue One the eGFR data expression patient -- expression, burden evaluate have to the between of response. this EGFR that cancer of IHC IHC, a by example, on level and To moderately based we've level a that reduction a the have have And had and with who in immunohistochemistry by patient the is by very retrospective the the assay. thing not association not for EGFR enrolled. of we pancreatic just actually of but shown had early our presentation, been as assay, low EGFR other depth response. partial date, who the patients XX% low seen as an confirmed shown in assessed this but doing level level expression we had on had expression as high has

I depends also -- think a more lot Peter, work done the yes, it itself. But to of there. more be on assay

So that we'll look to continue at relationship.

question from next comes Roger Your the of from Jefferies. Song line

A few questions us. from

are you you The do you the EGFR-related dose antitumor higher? relationship you between not beyond about since first one activity dose the dosing higher CRS, related how the can with profile, -- now about think how you're clearly level. the is mg, is, balance CDX think to question or correlate My How you at as ICANS, is dose efficacy XX. efficacy tolerability keep or do even confident more the and XX

Roger. Yes. Thanks,

kick me began X milligrams. response responses one at that in confirmed X that seen is there escalation a this the Let seeing, RECIST I'd micrograms. dose off. Remember X responses, at we're that say the we that that and dose we've

the seeing of effective consistent doses really the biologically modeling So where predictions our we're where be. actually range from range activity would of is with

know. So do Whether think We can or safety of we're zone. believe, we don't in help because think dose we will the that I not, however, we profile, the higher.

us, you in dose of that are trying engager forward T-cell concluded out. all and all look mean, the XXX to way to additional think milligrams And efficacy. I the field, figure the if to this went give end was of move significant the at XXX in kind tarlatimab, the I because they XX Amgen's didn't

will it do exceeded we're expectations our allow So I encouraged learn have more, we we'll see I takes that think where and and it escalate we've this dose it we'll further, but us. with safety and to think that to got clean profile us EGFR, very

your Amgen. Got related to question it. is partner, My follow-up

you Phase with make and of design study So by have looking the give the what update feedback also for the Ib order the for are you X shared understanding year, of the parties initial partner? And this end both decision? if in data, an any you will you and so, to

Yes, great questions.

take let's that have a Amgen. step back Amgen, with the we recap we and talk about agreement So little with just

them data do share obviously we emerges. Phase running we're it the So study. as And Ia with

are and tumor the Phase Phase is We would that get we to a enroll And obviously, in Amgen. quite And goal II we've the running. Phase Ib up specific to now, Ib exciting to we'll for once which with one Phase decision would of type, that transition Ib EGFR assume positive the also take jointly for responsible We running from this based be pancreatic. signal on seen. course, be would that

many lung patients patients -- some in the we few experience bring we neck, to -- and to in or head still more because a want -- So in we has types. do have not tumor we enrolled additional get unfolded, that example, those for way just enrollment

the strategy Before the Amgen we in be. about Ib would with conversation later Phase the what year have

ballpark really just It we of with could asked in or later think steps. -- data. It dialogue progress. a best excited point agreed that be question by this that's I We would update that additional we're of But time. from Amgen patients could to things. end couple on an the should obviously, the we've have the this -- So data have terms of could their year we our next But by at also from in with another a them. perspective data, operational so be them XX year, be on have update of

Piper it question, next Joe from Sandler. from comes the line of Catanzaro Your

question I guess what on it's small happening? that one in have that sort tox you reentering some EGFR of getting in indicative Is on Or tumor anything is seeing like that may my do and EGFR-mediated of maybe I or that EGFR maybe circulation? of tox is small unmasked historical a follow-up. I and amount normal cetuximab? guess say, the periphery T then you're getting amount X first you're And the experience, think is seeing, unmasked that is typical tissue, there cell targeting

Yes. couldn't have that that Grade Grade for over a mechanism otherwise unlocks very achievement, a really incidence this tumors to to me the the let low rash. We treatment-related patient patients pleased with in this all, rash Well, of because say Joe, the thanks That's opportunity shrink EGFR. think, first significant study. shrunk with it XX really, X the X of only X we're question. the with we be use

where rash Is hard see know may but coming very we're see -- all With We know it going a it's more to encouraged. So it we're do, they local? never work matter -- important to profile, benefit Obviously, drug, any are we you're what initially of because not to -- cancer. I the least involved say are and AEs, Wayne think very T risk type here and late-stage delivering pancreatic T which of that mentioned, rashes, cetuximab -- see -- as from? Grade rash, about going some early something the you're on we say they're Is that at about obviously would cell don't cells. to we much X, the we're for that is very very it's maculopapular might see some days, systemic? that. and They're maybe way pleased in we rash acneiform also, more patients X. typically with Grade

So the not mostly rash entire X, learn patients Grade XX% incidence manageable. XX of X study, it and just I going was entire effect we're have it's the more across think it, but worried because about about across the Grade X to to and all about we're X,

CRS mention quite encouraged we're So really by to profile, upside. frankly the really the Not surprised the which here. AE us profile to

my progression of lesion, event. was Was target sort we patient That's Wondering deep follow-up to bit on. cancer on I then it guess for it lesion. that could had a and subsequent more a if Yes. new maybe pancreatic If new that lesion, growth a going profile what's little see helpful. progression. a maybe you able response were that it of the elaborate and

I guess, say would Just anything there, you could interesting. be

over target on partial [indiscernible] appearance on confirmed I Yes, based The on of, lesion. treated did the in strikingly the with lesion response from target the burden. -- -- that. lesion X-milligram think, well tumor that XX% provide X I This a details progress the new growth of was patient new could patient of as reduction a on some as sorry, measurable non-step that dosing an with had is

that patient. well through the So particular patient course, did just progression nature the quite of clinically. that... based radiographic was that It progression on was But all that treatment the the on

squeeze Okay. going And more, maybe quick back an then in maybe to earlier if X could just I one, question.

CRC. like translating seems T on maybe could infiltration, going seeing you but mechanistically is think Just cell not maybe reduction. MSS you're to if you tumor speculate that's what more It on in

I'm So may going on sort of have what patients? of if in wondering other those be any you hypotheses

it's could how being we with overall, T-cell necessary very antigen, MHC mount interesting be combined engagers I that more well going think there response. typically antitumor these really work That be an when right? think mechanistically, what's tumor may mechanisms. we on. really the think nonrestricted But about as to CDX

actual more to specifically to combination field, in cancer. cancer about we're it CDX think there's about to I cells. cells Clearly, the objective could I what be responses. pancreatic learned engagers T it there CRC, think doing but in strategies tumor one's again, draws you think getting the T-cell we're how in attention We're kill get

and basic combinations. clinical quite we the terms do of clinical in think do also more there science work I So then work to some in of that intriguing. can It's

Darout from Your next Capital comes line of question, Etzer the Markets. it from BMO

current could sort then pancreatic you particularly it thinking potentially the you you thoughts through your how option if of wondering you're non-step this patients or versus the kind the the don't moving dosing, of said caught of I that there across if sort you've going to sort of step across already expand seen Just other don't of at -- about sort sort talk expressions for the that know response in that of X the about the And as had Is patients? maybe specifically on and expression an it the know patients kind study. opportunity that expressions? enrolled EGFR that the will far? look you're but of moving correctly. I EGFR so look you've Or forward, in folks you sort EGFR to I is of at if the

Yes. Thanks, Etzer.

or moving based significantly do a sorts. think to of we decision on non-step, experience doses of say us allowing doses. I on will forward with our target response to more here a get there's strategies, higher haven't terms yet. In And step we likely Ib dose But it's to date, that because obviously step our Phase made that be would

only likely think of also gain the experience Phase well. also -- likely in be take but want will as pancreatic, than not we'll to to more dose schedule you learned more further about So Ib there other candidate, X into project in considerations, Optimus when take drug and tumors to

-- actually by EGFR how assays just -- put it's it's I surprising for IHC, this EGFR assay of not for or terms should the that it's perfect. available EGFR In

low ADC straightforward moving a -- for kill can T so killing -- required tumor of doesn't thing early data we're target activity. X where how type where forward, to would sure to be our on high be it target is multiple that the T-cell because this amplified would of because seem want These tumor levels of mechanism And drugs not is X cells. the from cell engagers like mechanism just predicted particularly much at rely active you it

that's we've on based think in far. or be I EGFR and So may we we've what go-forward more basis seen why selection leveraging do there, needing a not to got we're on -- so

Rama JPMorgan. Anupam question, next from it of the line from Your comes

you of X Can -- comment that you was lines of PDAC think therapy treatments a the I of the in that might there prior number predictive otherwise, or was study baseline be response. anything said a case characteristics,

other EGFR I didn't you comment, think stable first was on their and duration? question, I expression correlate. based the this, missed the patients, sorry can X I'm disease And then if what

no, pretty not cells question of first certainly really. predictive did have and I'll levels the from to the are could take a is was of that think and response. I that we showed intriguing, terms all pretty And in CDX-positive in patients. show Again, patient patient been anything which of I'd say, have the cytotoxic pretreatment could of characteristics aside response late-life biopsy EGFR, which with -- contributed a high said, T pretreatment, slide Wayne of a these

that it have -- don't data whole across every That's And is get We that's something for intriguing. so study. data difficult patient, that to have observed. we the systematically, but

address the of terms question real can disease, stable quick. that Wayne In

Yes.

was had able smattering it a smattering stable to that showed swim to number a disease patients the -- response disease. presentation, were in included we stable responses. progressive otherwise, achieve least by a through through disease during tumor and as that -- So maintain tumor at followed who to the But then lane were X of and plot of stable patients tumor there able disease were durable patients a

are very these that are again, patients or for -- disease. everyone priors. as very part, it's think knows, do pancreatic to These had -- X who, most the important I X it's reemphasize rapidly progressing the a

is we really exciting so a so yes, this -- this And data. think

Kapoor Your next from line comes from H.C. Mitchell of the it Wainwright. Instructions] question, [Operator

how the comment those time? for to patients what seeing wanted ask in positive Congrats could on slider data. other depth tumor about reductions well, like. evolve? these just broadly I a a on look trend response over we seeing Are are the -- might tumor total Or if reductions the X you plot I you guess, with of patients

Yes. I days. mean it's early

waterfall those of them X them pancreatic in X the patients, think patients, I and see plot. are obviously, the can you

think continues, there terms I fact encouragement the of in the there's that here. pushing dose escalation keep we'll

[ point, it's think spider this at I relatively the say plot will fair So to ] immature. be

patient? Okay. duration could follow-up of response the just how you partial that other And comment much And confirmed patient on ahead?

response, treatment That approximately patient, X-milligram and before partial again, about on confirmed had XX progressive -- schedule, dosing was non-step treated on at patient study study that the remained disease. weeks having

McCarthy, questions. remarks. back Chairman Thank for like the to and Sean turn to would now I'm CEO, closing showing conference I further you. Dr. no And CytomX'

far thanks, the we and our listening And biggest we providing CytomX for the year for we very you proceeds. as Thank difference updates much, to in patients. additional made Great. and to look company for continue forward in to long the everyone, so progress terrific build can make XXXX, as has term today.

much. evening. good very Have you thank so And a

conference Thank This you today's for now may participating, concludes call. and you disconnect.